SIGLEC9 and acute myeloid leukemia: In sub-group analysis, AML patients with WBC count ≤ 20 × 109/L had significantly reduced overall survival probability when they had higher expression of siglec9 (p = 0.002, HR 2.66, CI 1.44–4.90), siglec10 (p = 0.001, HR 2.69, CI 1.47–4.93), siglec14 (p = 0.035, HR 1.90, CI 1.05–3.45) or siglec16 (p = 0.012, HR 2.16, CI 1.18–3.95) (Fig. 5C).